MNPR Monopar Therapeutics Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 12, 2026
$77.97
· of 52w range
· above low
· to high
$50.0752w low
$124.8252w high
Market Cap (MRQ)
$523M
Revenue
$0
your badges
52W Range
$50–$125
Analyst Rating
BUY
Price Target
$128
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
MNPR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$77.97
Market Cap (MRQ)
$523M
Revenue
$0
52W Range
$50–$125
MNPR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Aug. 13, 2024 | 1-for-5 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$02016-12-31 → 2025-12-31
Net margin·2020-12-31 → 2022-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | MNPR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 4.05Y avg ≈8.2 | ≈8.2 | 4.7 | Overvalued | |
| Price / Tangible Book | 3.25Y avg ≈7.2 | ≈7.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | MNPR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 33.6 | · | 9.5 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | MNPR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue / Employee | ≈$0.00 | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-65.4%
Next Report
Nov 11, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $-0.62 | $-0.63 | 2.1% |
| March 31, 2026 | May 14, 2026 | $-0.46 | $-0.85 | 46.0% |
| Dec. 31, 2025 | $-0.64 | $-0.50 | -27.3% | |
| Sept. 30, 2025 | $-0.48 | $-0.44 | -9.4% | |
| June 30, 2025 | $-0.35 | $-0.48 | 27.3% | |
| March 31, 2025 | $-0.38 | $-0.69 | 45.2% | |
| Dec. 31, 2024 | $-2.75 | $-0.43 | -541.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | · | · | · | $0 | $0 | $0 | |
| R&D Expense | $10M | $13M | $6M | $8M | $6M | $4M | $2M | $2M | $935.3K | |
| SG&A Expense | $7M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | |
| Operating Expenses | $17M | $16M | $9M | $11M | $9M | $7M | $4M | $3M | $17M | |
| Operating Income | $-17M | $-16M | $-9M | $-11M | $-9M | $-7M | $-4M | $-3M | $-17M | |
| Interest Income | $3M | $404.0K | $429.0K | · | · | · | · | · | · | |
| Pretax Income | $-14M | $-16M | $-8M | · | · | · | · | $-3M | $-17M | |
| Income Tax | $800 | $800 | $800 | $800 | $0 | $18.4K | $0 | $-70.8K | $-3.6K | |
| Net Income | $-14M | $-16M | $-8M | $-11M | $-9M | $-6M | $-4M | $-3M | $-17M | |
| EPS (Basic) | $-1.85 | $-4.11 | $-3.04 | $-0.83 | · | · | · | · | · | |
| Shares (Basic) | 7,411,121 | 3,790,202 | 2,764,790 | 12,718,166 | 12,471,217 | · | · | · | · | |
| EBITDA | · | $-16M | $-9M | $-11M | $-9M | $-7M | $-4M | $-3M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62M | $46M | $7M | $8M | $20M | $17M | $13M | $7M | $9M | |
| Other Current Assets | $63.7K | $78.9K | $66.4K | $46.0K | $217.7K | $62.7K | $15.7K | · | · | |
| Current Assets | $140M | $60M | $7M | $13M | $21M | $17M | $13M | $7M | $9M | |
| Other Non-current Assets | · | · | · | · | $0 | $68.9K | $122.4K | $65.7K | · | |
| Total Assets | $141M | $60M | $7M | $13M | $21M | $17M | $13M | $7M | $10M | |
| Accounts Payable | $3M | $2M | $2M | $3M | $2M | $1M | $724.2K | $399.6K | $311.9K | |
| Current Liabilities | $3M | $5M | $2M | $3M | $2M | $1M | $724.2K | $399.6K | $311.9K | |
| Capital Leases | $154.9K | $0 | $0 | $8.4K | $0 | · | · | · | · | |
| Total Liabilities | $3M | $5M | $2M | $3M | $2M | $1M | $724.2K | $399.6K | $311.9K | |
| Common Stock | $6.7K | $6.1K | $3.0K | $12.9K | $12.6K | $11.5K | $10.6K | $9.3K | $9.3K | |
| Paid-in Capital | · | · | · | $62M | $60M | $48M | $39M | $29M | $28M | |
| Retained Earnings | $-90M | $-76M | $-60M | $-52M | $-41M | $-32M | $-26M | $-22M | $-18M | |
| AOCI | $131.4K | $36.0K | $-14.1K | $8.9K | $-3.2K | $-7.9K | $-11.0K | $-2.4K | $0 | |
| Stockholders' Equity | $138M | $55M | $6M | $10M | $19M | $16M | $13M | $7M | $10M | |
| Liabilities + Equity | $141M | $60M | $7M | $13M | $21M | $17M | $13M | $7M | $10M | |
| Shares Outstanding | 6,692,140 | 6,102,560 | 2,980,900 | 12,946,573 | 12,598,125 | 11,453,465 | 10,587,632 | 9,291,421 | 9,291,421 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $1M | $2M | $2M | · | · | · | · | · | |
| Deferred Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-71.6K | $0 | |
| Operating Cash Flow | $-12M | $-6M | $-8M | $-7M | $-7M | $-5M | $-3M | $-3M | $-3M | |
| Investing Cash Flow | $-63M | $-14M | $5M | $-5M | $0 | · | · | · | · | |
| Stock Issued | $0 | $4M | $2M | $109.3K | · | $8M | $0 | $0 | $5M | |
| Stock Repurchased | $35M | $0 | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $4M | $2M | · | · | $8M | · | $0 | · | |
| Financing Cash Flow | $92M | $59M | $2M | $32.9K | $11M | $8M | $9M | $-206.3K | $10M | |
| Net Change in Cash | $16M | $39M | $-920.1K | $-12M | $4M | $4M | $6M | $-3M | $7M | |
| Taxes Paid | · | · | · | · | $0 | $-11.1K | $53 | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -49611.0% | -37992.2% | -7947.2% | · | · | · | |
| Net Margin | · | · | · | -49511.0% | -37892.2% | -7697.7% | · | · | · | |
| EBITDA Margin | · | · | · | -49611.0% | -37992.2% | -7947.2% | · | · | · | |
| ROA | · | -46.1% | -81.7% | -62.3% | -48.7% | -41.7% | -40.9% | -37.4% | · | |
| ROE | · | -52.0% | -137.8% | -93.1% | -45.3% | -38.0% | -49.0% | -44.5% | · | |
| ROIC | · | -29.4% | · | · | · | · | · | -48.1% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | · | 4.2 | 4.2 | · | 14.3 | 18.3 | 18.3 | · | |
| Quick Ratio | · | · | 4.1 | 2.6 | · | 14.2 | 18.2 | 17.3 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $9.02 | $0.37 | $0.78 | $1.50 | $1.37 | $1.19 | $0.74 | · | |
| Cash / Share | · | $7.51 | $0.49 | $0.63 | $1.61 | $1.46 | $1.25 | $0.74 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income TTM | $-14M | $-16M | $-8M | $-11M | $-9M | $-6M | $-4M | $-3M | $-17M | |
| Market Cap | · | $134M | $25M | $153M | $202M | $350M | $879M | · | · | |
| P/B | · | 2.4 | 4.5 | 15.2 | 10.7 | 22.3 | 69.6 | · | · | |
| P / Tangible Book | 3.2 | 2.4 | 4.5 | 15.2 | 10.7 | 22.3 | · | · | · | |
| P / Cash Flow | · | -21.0 | -3.2 | -21.2 | 27.6 | -75.2 | -291.2 | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $5M | $3M | $4M | $3M | $2M | $2M | $10M | $984.3K | $1M | $966.1K | $1M | $1M | $2M | $2M | $2M | $2M | |
| SG&A Expense | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $590.6K | $657.8K | $757.3K | $876.4K | $749.5K | $733.5K | $871.7K | $806.0K | $675.1K | |
| Operating Expenses | $7M | $5M | $6M | $4M | $3M | $3M | $11M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $2M | |
| Operating Income | $-7M | $-5M | $-6M | $-4M | $-3M | $-3M | $-11M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-3M | $-3M | $-2M | |
| Interest Income | $1M | $1M | $954.4K | $655.5K | $780.8K | $596.8K | $149.0K | $99.3K | $73.5K | $82.2K | $98.1K | $112.3K | · | · | · | · | |
| Net Income | $-5M | $-4M | $-5M | $-3M | $-2M | $-3M | $-11M | $-1M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-3M | $-2M | |
| EPS (Basic) | $-0.62 | $-0.46 | $-0.64 | $-0.48 | $-0.35 | $-0.38 | $-2.74 | $-0.37 | $-0.49 | $-0.51 | $-2.00 | $-0.69 | $-0.16 | $-0.19 | $-0.23 | $-0.19 | |
| Shares (Basic) | 8,542,450 | 8,535,443 | · | 7,123,849 | 6,998,082 | 6,987,381 | · | 3,520,398 | 3,502,927 | 3,195,963 | · | 2,823,680 | 13,420,029 | 13,105,831 | · | 12,754,685 | |
| EBITDA | $-7M | $-5M | · | $-4M | $-3M | $-3M | · | $-2M | $-2M | $-2M | · | $-2M | $-2M | $-3M | · | $-2M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $53M | $62M | $128M | $40M | $40M | $46M | $6M | $6M | $8M | $7M | $6M | $7M | $6M | $8M | $14M | |
| Other Current Assets | $464.7K | $250.9K | $63.7K | $414.8K | $497.3K | $523.6K | $78.9K | $49.6K | $61.0K | $119.0K | $66.4K | $73.2K | $109.9K | $106.8K | $46.0K | $55.7K | |
| Current Assets | $135M | $138M | $140M | $144M | $54M | $55M | $60M | $6M | $7M | $9M | $7M | $9M | $10M | $12M | $13M | $14M | |
| Total Assets | $135M | $138M | $141M | $144M | $54M | $55M | $60M | $6M | $7M | $9M | $7M | $9M | $10M | $12M | $13M | $14M | |
| Accounts Payable | $4M | $2M | $3M | $3M | $2M | $1M | $2M | $1M | $1M | $1M | $2M | $2M | $3M | $3M | $3M | $2M | |
| Current Liabilities | $4M | $2M | $3M | $3M | $2M | · | $5M | · | · | · | · | $2M | $3M | $3M | $3M | $2M | |
| Capital Leases | $107.8K | $131.6K | $154.9K | $70.9K | $80.4K | · | $0 | · | · | · | · | $0 | $0 | $0 | $8.4K | $20.9K | |
| Total Liabilities | $4M | $3M | $3M | $3M | $2M | $1M | $5M | $1M | $1M | $1M | $2M | $2M | $3M | $3M | $3M | $2M | |
| Common Stock | $6.7K | $6.7K | $6.7K | $6.7K | $6.1K | $6.1K | $6.1K | $3.5K | $17.6K | $17.5K | $3.0K | $14.2K | $13.9K | $13.2K | $12.9K | $12.9K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | · | · | $63M | · | $61M | |
| Retained Earnings | $-99M | $-93M | $-90M | $-84M | $-81M | $-78M | $-76M | $-65M | $-64M | $-62M | $-60M | $-58M | $-56M | $-54M | $-52M | $-49M | |
| AOCI | $91.3K | $98.5K | $131.4K | $11.7K | $77.6K | $-21.8K | $36.0K | $-11.0K | $8.3K | $4.2K | $-14.1K | $3.9K | $7.2K | $31.8K | $8.9K | $43.0K | |
| Stockholders' Equity | $131M | $135M | $138M | $142M | $52M | $54M | $55M | $5M | $6M | $7M | $6M | $7M | $8M | $9M | $10M | $13M | |
| Liabilities + Equity | $135M | $138M | $141M | $144M | $54M | $55M | $60M | $6M | $7M | $9M | $7M | $9M | $10M | $12M | $13M | $14M | |
| Shares Outstanding | 6,712,172 | 6,699,062 | 6,692,140 | 6,662,930 | 6,127,457 | 6,115,214 | 6,102,560 | 3,525,079 | 17,601,827 | 17,484,175 | 2,980,900 | 14,198,438 | 13,898,081 | 13,222,056 | 12,946,573 | 12,855,735 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $2M | $1M | $1M | $1M | $1M | $278.6K | $199.1K | $334.4K | $328.7K | $474.2K | $474.1K | $473.3K | $476.2K | $393.4K | $390.7K | |
| Operating Cash Flow | $-3M | $-3M | $-3M | $-2M | $-1M | $-6M | $-2M | $-1M | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M | $-1M | $-2M | |
| Investing Cash Flow | $4M | $-6M | $-62M | $-2M | $1M | $-325.8K | $-14M | $985.7K | $-2.4K | $-983.3K | $3M | $-13.1K | $3M | $-983.4K | $-5M | $0 | |
| Stock Issued | · | · | $0 | $0 | $0 | $0 | $1M | $0 | $-1 | $3M | $339.9K | $254.9K | $657.8K | $821.6K | $109.3K | $0 | |
| Stock Repurchased | · | · | $0 | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $3M | · | · | · | · | · | · | |
| Financing Cash Flow | $-647.4K | $-200.2K | $-384.7K | $92M | $-316.8K | $-115.7K | $56M | $-16.5K | $-9.9K | $3M | $334.5K | $246.7K | $641.2K | $804.8K | $138.7K | $-23.7K | |
| Net Change in Cash | $213.5K | $-9M | $-66M | $88M | $-209.5K | $-6M | $40M | $-99.8K | $-2M | $541.5K | $2M | $-2M | $1M | $-2M | $-6M | $-2M |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | -2434.6% | -2097.5% | · | -1840.4% | -1815.8% | -2790.5% | · | -31272.3% | |
| Net Margin | · | · | · | · | · | · | · | · | -2334.6% | -1997.5% | · | -1740.4% | -1715.8% | -2690.5% | · | -31172.3% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | -2434.6% | -2097.5% | · | -1840.4% | -1815.8% | -2790.5% | · | -31272.3% | |
| ROA | -5.6% | -4.0% | · | -4.6% | -8.0% | -8.2% | · | -17.8% | -19.6% | -15.8% | · | -17.0% | -16.2% | -16.3% | · | -13.0% | |
| ROE | -5.8% | -4.1% | · | -4.7% | -8.4% | -8.6% | · | -22.6% | -24.6% | -20.0% | · | -20.4% | -19.7% | -18.8% | · | -14.2% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 33.6 | 56.0 | · | 56.1 | 33.9 | · | · | · | · | · | · | 4.3 | 4.1 | 4.1 | · | 7.5 | |
| Quick Ratio | 13.1 | 21.4 | · | 49.7 | 24.9 | · | · | · | · | · | · | 2.8 | 2.9 | 2.0 | · | 7.5 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $19.50 | $20.21 | · | $21.25 | $8.52 | $8.76 | · | $1.40 | $0.35 | $0.43 | · | $0.47 | $0.56 | $0.68 | · | $0.97 | |
| Cash / Share | $7.86 | $7.84 | · | $19.16 | $6.45 | $6.49 | · | $1.71 | $0.35 | $0.45 | · | $0.39 | $0.52 | $0.43 | · | $1.11 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Net Income TTM | $-18M | $-15M | · | $-19M | $-17M | $-17M | · | $-6M | $-7M | $-8M | · | $-9M | $-10M | $-10M | · | $-10M | |
| Market Cap | $621M | $367M | · | $544M | $219M | $223M | · | $24M | $64M | $60M | · | $44M | $59M | $92M | · | $98M | |
| P/B | 4.7 | 2.7 | · | 3.8 | 4.2 | 4.2 | · | 4.8 | 10.5 | 8.0 | · | 6.7 | 7.6 | 10.3 | · | 7.8 | |
| P / Tangible Book | 4.7 | 2.7 | · | 3.8 | 4.2 | 4.2 | · | 4.8 | 10.5 | 8.0 | · | 6.7 | 7.6 | 10.3 | · | 7.8 | |
| P / Cash Flow | · | -105.7 | · | · | · | -39.3 | · | · | · | -36.0 | · | · | · | -40.5 | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | · | · |
| Operating Margin % | · | · | · | -49611.0% | -37992.2% |
| Net Income | $-14M | $-16M | $-8M | $-11M | $-9M |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | · | · | 4.2 | 4.2 | · |
| Quick Ratio | · | · | 4.1 | 2.6 | · |
No data for this statement
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 98 filers · $544.8M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
98
Value held
$544.8M
New positions
29
Exited positions
14
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 29 (+10 vs prior Q) | 14 (+5 vs prior Q) | 31 (-2 vs prior Q) | 24 (+6 vs prior Q) | -1.3M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $72,062,327 | 1,317,410 | 13.23% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $61,776,696 | 667,207 | 11.34% | Shares |
| BlackRock, Inc. | $32,297,151 | 348,819 | 5.93% | Shares |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $29,975,550 | 323,745 | 5.50% | Shares |
| Saturn V Capital Management LP | $28,885,858 | 311,976 | 5.30% | Shares |
| Siren, L.L.C. | $25,010,226 | 270,118 | 4.59% | Shares |
| ADAR1 Capital Management, LLC | $20,147,121 | 217,595 | 3.70% | Shares |
| Polar Capital Holdings Plc | $19,857,685 | 214,469 | 3.65% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $19,417,141 | 209,711 | 3.56% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $19,369,365 | 209,195 | 3.56% | Shares |
| VANGUARD GROUP INC | $19,186,185 | 293,816 | 3.52% | Shares |
| TCG Crossover Management, LLC | $18,826,047 | 203,327 | 3.46% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $14,669,682 | 158,437 | 2.69% | Shares |
| ORBIMED ADVISORS LLC | $14,575,796 | 157,423 | 2.68% | Shares |
| Candriam S.C.A. | $13,258,989 | 143,339 | 2.43% | Shares |
| Balyasny Asset Management L.P. | $12,457,336 | 134,543 | 2.29% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $10,426,384 | 112,578 | 1.91% | Shares |
| Alyeska Investment Group, L.P. | $9,259,000 | 100,000 | 1.70% | Shares |
| STATE STREET CORP | $8,569,297 | 92,551 | 1.57% | Shares |
| Vivo Capital, LLC | $8,379,395 | 90,500 | 1.54% | Shares |
| Driehaus Capital Management LLC | $7,781,264 | 84,040 | 1.43% | Shares |
| Bank of New York Mellon Corp | $7,124,057 | 76,942 | 1.31% | Shares |
| Vestal Point Capital, LP | $7,011,563 | 75,727 | 1.29% | Shares |
| Longaeva Partners L.P. | $5,169,670 | 55,834 | 0.95% | Shares |
| NEUBERGER BERMAN GROUP LLC | $5,110,413 | 55,194 | 0.94% | Shares |
| MILLENNIUM MANAGEMENT LLC | $4,658,295 | 50,311 | 0.86% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4,519,873 | 48,816 | 0.83% | Shares |
| Ikarian Capital, LLC | $4,431,450 | 47,861 | 0.81% | Shares |
| CITADEL ADVISORS LLC | $3,426,200 | 37,004 | 0.63% | Shares |
| NORTHERN TRUST CORP | $3,207,411 | 34,641 | 0.59% | Shares |
| DEUTSCHE BANK AG\ | $2,871,031 | 31,008 | 0.53% | Shares |
| STEMPOINT CAPITAL LP | $2,789,274 | 30,125 | 0.51% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,618,445 | 28,280 | 0.48% | Shares |
| UBS Group AG | $2,523,911 | 27,259 | 0.46% | Shares |
| MORGAN STANLEY | $1,659,121 | 17,919 | 0.30% | Shares |
| AMERIPRISE FINANCIAL INC | $1,648,102 | 17,800 | 0.30% | Shares |
| GOLDMAN SACHS GROUP INC | $1,496,347 | 16,161 | 0.27% | Shares |
| Russell Investments Group, Ltd. | $1,374,961 | 14,850 | 0.25% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $1,360,055 | 14,689 | 0.25% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1,291,908 | 13,953 | 0.24% | Shares |
| Ishara Investments LP | $1,138,857 | 12,300 | 0.21% | Shares |
| TWO SIGMA INVESTMENTS, LP | $1,134,413 | 12,252 | 0.21% | Shares |
| Trexquant Investment LP | $1,111,450 | 12,004 | 0.20% | Shares |
| Creative Planning | $719,239 | 7,768 | 0.13% | Shares |
| XTX Topco Ltd | $605,168 | 6,536 | 0.11% | Shares |
| Nuveen, LLC | $553,688 | 5,980 | 0.10% | Shares |
| BARCLAYS PLC | $540,077 | 5,833 | 0.10% | Shares |
| RHUMBLINE ADVISERS | $521,271 | 5,630 | 0.10% | Shares |
| GERBER, LLC | $518,597 | 5,601 | 0.10% | Shares |
| Virtus Investment Advisers, LLC | $506,838 | 5,474 | 0.09% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Tactic Pharma LLC, Robinson Chandler, Brown Michael J ×4 filings | Jan. 30, 2026 | 4.50% | Amendment | · | SEC |
| Monopar Therapeutics, Hendricks Diane, Leo Karl, Pharma Investments LLC | Feb. 7, 2025 | 13.40% | Amendment | · | SEC |
| GEM PHARMACEUTICALS LLC, DIANE HENDRICKS, KARL LEO, ARTHUR KLAUSNER, PHARMA INVESTMENTS LLC | Dec. 23, 2019 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 18 insiders · 7 officers · 9 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Robinson Chandler | Chief Executive Officer | Sept. 30, 2026 M | 104,724 | 0 | 4 | $-2,556,851 |
| Quan Anh Vu | Chief Financial Officer | Sept. 30, 2026 M | 2,655 | 1 | 0 | $104,925 |
| Karthik Radhakrishnan | Chief Financial Officer | Oct. 28, 2024 P | 1,550 | 0 | 0 | $0 |
| Andrew Cittadine | Chief Operating Officer | Sept. 30, 2026 M | 58,054 | 0 | 0 | $0 |
| Susan Rodriguez | CCSO | March 2, 2026 A | · | 0 | 0 | $0 |
| Mazar Andrew Paul | Chief Scientific Officer | March 31, 2022 M | 22,125 | 0 | 0 | $0 |
| Jose Octavio Pinto Costa Filho | Chief Medical Officer | July 12, 2021 A | · | 0 | 0 | $0 |
| Kim R Tsuchimoto | Director | Aug. 26, 2026 M | 0 | 0 | 12 | $-911,134 |
| Raymond Anderson | Director | Aug. 25, 2026 M | 5,373 | 0 | 6 | $-703,024 |
| Nicole Sweeny | Director | June 26, 2026 A | · | 0 | 0 | $0 |
| Arthur J Klausner | Director | Dec. 18, 2025 S | 8,762 | 0 | 2 | $-343,889 |
| Lavina Talukdar | Director | Dec. 2, 2025 A | · | 0 | 0 | $0 |
| Christopher M Starr | Director | Dec. 2, 2025 A | 5,173 | 0 | 0 | $0 |
| Brown Michael J | Director | Dec. 31, 2023 M | 235,863 | 0 | 0 | $0 |
| Hendricks Diane | 10% owner | Dec. 16, 2025 J | 567,580 | 0 | 0 | $0 |
| TacticGem LLC | 10% owner | Dec. 9, 2024 J | 0 | 0 | 0 | $0 |
| Leo Karl | 10% owner | Dec. 18, 2019 P | 314 | 0 | 0 | $0 |
| Patrice Rioux | · | Aug. 26, 2026 M | 5,065 | 0 | 1 | $-111 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 15 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 1.21% | 5,200 NS | July 31, 2026 | N-PORT |
| IWC · iShares Trust | 0.12% | 15,317 SH | Sept. 11, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.08% | 18,350 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 2,949 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 116,579 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.02% | 2,170 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 25,913 SH | Aug. 19, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.01% | 1,184 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.01% | 10,465 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 9,936 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 1,853 SH | Sept. 9, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 45,173 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 159,786 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 420 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 31,559 SH | Sept. 11, 2026 | Daily |
MNPR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 19 analysts
BUY
Median target
$130.00
+66.7%
4 21.1%
Strong Buy
13 68.4%
Buy
2 10.5%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
13 analysts · 2026-09-27Mean target $127.62 +63.7%
← Below all targets
Current price $77.97
Low$100.00
Mean$127.62
High$145.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| MNPR | · | · | · | · | · | · |
| CBIO | $327M | -24.2 | -86.7% | -1419.6% | -90.0% | · |
| ALT | $400M | -3.6 | 105.0% | -214861.0% | -45.6% | · |
| ZURA | · | · | · | · | · | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| PROK | · | · | 1075.0% | -7725.2% | 6.9% | · |
| CAPR | $1.66B | -12.8 | -11.6% | · | -51.1% | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | · |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | · |
| OVID | $212M | -4.0 | 1181.3% | -240.1% | -18.7% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026